Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Current Status of Sentinel Lymph Node Biopsy for Melanoma: Evidence and Practical Considerations
Description
Doctor Christina Angeles, a surgical oncology professor at the University of Michigan, discusses the current role of Sentinel Lymph Node Biopsy (SLNB) in melanoma treatment. SLNB is a minimally invasive procedure used for staging that helps determine the likelihood of melanoma spreading, rather than detecting it. It involves injecting a radioactive dye to identify primary drainage lymph nodes. The procedure is recommended for patients with a heighted risk (T1B and above) of positive nodes but is not suggested for low-risk patients (T1A). Doctor Angeles highlights the distinction in SLNB's efficacy for intermediate thickness melanoma (T2, T3) where long-term follow-up has shown survival improvements, contrasting with thick disease (T4) where SLNB does not enhance survival outcomes. Challenges include deciding the necessity of SLNB, given that approximately 85% of patients with T1 or T2 melanoma have negative results. The presentation introduces the Merlin trial focusing on gene expression profiling to better predict low-risk patients, potentially reducing unnecessary surgeries. The future of melanoma management may integrate advanced genomic testing with existing surgical and therapeutic approaches, aiming to minimize invasive procedures while maintaining effective patient outcomes.
View moreConclusions
- Sentinel lymph node biopsy (SLNB) is a critical staging procedure for melanoma patients, particularly for intermediate thickness cases, as it can improve survival rates.
- For melanoma patients with T1b and T2a stages, SLNB is recommended when the risk of positive lymph nodes is over 5%.
- Approximately 85% of patients who undergo SLNB may have negative results, suggesting potential overuse in low-risk patients.
- Current guidelines suggest considering the MERLIN test for patients with T1b to T2a melanomas when discussing SLNB procedures.
- Efforts are underway to use gene expression profile (GEP) tests to better identify low-risk patients who may forgo SLNB.
- Not all patients identified as stage IIIA by SLNB have the same prognosis; further stratification is necessary for optimal treatment planning.
- Intermediate thickness melanoma patients show a notable survival advantage with the use of SLNB, validating its utility in this context.
- Adjuvant therapies, such as immune checkpoint inhibitors, may not benefit all patients equally, indicating a need for better patient selection criteria.
- Valsecchi et al. JSO 2011
- Wong et al. JSO 2012
- Boland and Gershenwald. Cancer Treat Res. 2016
- Morton et al, N Engl J Med 2014
- Gershenwald et al. CA Cancer J Clin. 2017
- Wrightson et al. ASO 2003
- Eggermont A et al. E J Cancer 2019
- Eggermont et al. NEJM 2018
- Hosein et al. J Surg Onc. 2023
- Drebin et al. J Am Coll Surg. 2024
- Bellomo et al. JCO Precis Oncol. 2020
- Mulder et al. Br. J. Dermatol. 2021
- Yousaf et al. Int. J. Dermatol.2021
- Johansson et al. Eur. J. Surg. Oncol. 2021
- Melanoma Cutaneous NCCN Guidelines 2.2025